PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL — Stella

Recruiting

Back to Natural Killer/T-cell Lymphoma trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

China

Ruijin Hospital, Shanghai JiaoTong University School of Medicine, Shanghai

Key details

Phase

Safety & dosing

Sponsor

Ruijin Hospital

Enrollment target

~47 participants

Started

March 2026

Primary completion

February 2029

Age range

18 Years and older

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov